As the largest independent microcap conference in the U.S., the 2025 Microcap Conference brought together over 750 institutional investors, venture capital representatives, and industry experts from around the world. This prestigious event provided Baird Medical with an exceptional platform to highlight its technological advancements and explore strategic opportunities. At the conference, Baird Medical demonstrated its cutting-edge minimally invasive microwave ablation technology, drawing significant attent ...

On October 2, 2024 (U.S. Eastern Time), Baird Medical successfully listed on the Nasdaq Stock Market, marking a significant milestone in its international growth strategy. This listing reinforces the Company's commitment to innovation, global market expansion, and enhancing shareholder value as it continues to pioneer cutting-edge medical solutions. PatentsIn 2024, Baird Medical further expanded its intellectual property portfolio, securing patents that enhance MWA technology and production efficiency: Inve ...

The NASIT Conference is a premier forum for education, research, and collaboration in thyroid interventions, and Baird Medical is honored to participate in this key industry event. The Company's invitation highlights its growing prominence in the field of microwave ablation while offering a valuable opportunity to engage with global experts, industry leaders, and potential partners. As a returning participant, Baird Medical is excited to contribute to discussions on the latest advancements in MWA technology ...

NEW YORK, Jan. 23, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in microwave ablation technology (MWA), announced today that it will participate in the highly anticipated Microcap Conference, set to take place at the Borgata Hotel in Atlantic City, New Jersey, from January 28 to January 30, 2025. Baird Medical specializes in the design and development of cutting-edge needles and apparatus for microwave ablation of thyroid nodules. Th ...

Core Insights - Baird Medical is expanding its presence into San Francisco as part of its U.S. growth strategy, following its participation in the J.P. Morgan Health Conference [1] - The company has received FDA 510(k) clearance for its Microwave Ablation (MWA) technology, which has been successfully used to treat hundreds of patients, demonstrating significant recovery and positive outcomes [3] - Collaboration with medical specialists and comprehensive training initiatives are being implemented to enhance physician education and awareness of MWA technology [4] Company Overview - Baird Medical is a leader in minimally invasive microwave ablation technology, providing advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer [5] - The company is publicly traded on NASDAQ under the ticker BDMD and is focused on improving patient care through innovative medical devices [5] Market Recognition - Dr. Terrence K. Trapp, an otolaryngologist, has integrated Baird Medical's MWA system into his practice, indicating a growing interest in minimally invasive treatments for thyroid nodules [2] - Dr. Emad Kandil from Tulane University has performed over 100 MWA procedures, highlighting the clinical potential and increasing recognition of Baird Medical's innovations within the medical community [3]

Following its successful debut on Nasdaq in October 2024, Baird Medical connected with healthcare investors and industry leaders during the week of the conference, engaging in meaningful discussions on the company's advancements in microwave ablation technology and its commitment to improving patient outcomes. "Being in San Francisco during the J.P. Morgan Healthcare Conference provided a valuable opportunity to engage with shareholders, innovators, and advisors in the healthcare sector," said Haimei Wu, Ch ...

Led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, the session welcomed participation from Dr. Sean P. Nikravan, MD, FACE, an endocrinologist based in Newport Beach, CA, and Dr. Erin H. Lin, DO, a specialist in Surgical Oncology and General Surgery from the University of California, Irvine. Both physicians had the opportunity to observe seven live MWA procedures, refine advanced techniques, and evaluate the unique capabilities of this groundbreaking t ...

Group 1 - The forum organized by healthcare institutions in Guangdong focused on advancements in the diagnosis and treatment of parathyroid diseases, serving as a platform for academic discussions and clinical expertise exchange [1] - Baird Medical participated in the forum to engage with key opinion leaders and enhance its understanding of clinical needs, highlighting its commitment to advancing minimally invasive medical technologies [2][5] - The company presented its microwave ablation technology, which offers precise and efficient treatment options for endocrine conditions, including parathyroid diseases [9] Group 2 - Baird Medical is recognized as a leading provider of minimally invasive microwave ablation technology, aimed at improving patient care through innovative medical devices [6] - The company's focus includes treatment solutions for various conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer [6] - Baird Medical's participation in the forum reflects its dedication to supporting medical advancements in endocrine disease management [6]

Core Insights - Baird Medical showcased its advancements in thyroid treatment, particularly its microwave ablation (MWA) technology, at the Guangdong Thyroid Surgery Committee Annual Meeting [1][2] - The event served as a platform for collaboration and knowledge-sharing among leading experts in thyroid surgery, emphasizing the importance of minimally invasive surgical techniques [2][3] Company Overview - Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, focusing on treatment solutions for thyroid nodules, breast disease, uterine fibroids, and liver cancer [4] - The company is publicly traded on NASDAQ and is committed to enhancing patient care through precision, efficiency, and safety in its innovative medical devices [4]

Led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, the program welcomed Dr. Ernest O. Asamoah, an endocrinologist from Indianapolis, IN, and Dr. John W. Sistrunk, an endocrinologist from Jackson, MS. Both physicians observed seven live MWA cases, participated in in-depth discussions, and engaged in hands-on practice with the equipment. Dr. Kandil, who has performed over 80 MWA procedures, recently presented at the American Thyroid Association (ATA) an ...